REGN-1400 is a fully human monoclonal antibody inhibitor targeting ErbB3. By inhibiting ErbB3, REGN-1400 blocks associated signaling pathways to reduce tumor cell proliferation. It shows potential for research in solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN).
Target:
EGFR
* VAT and and shipping costs not included. Errors and price changes excepted
